COMMUNIQUÉS West-GlobeNewswire

Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents
12/08/2026
-- New U.S. and international patents complement existing delivery system patents, extending global IP coverage for the FemBloc solution -- ATLANTA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a [...]
LiveWorld Reports Second Quarter 2026 Financial Results
12/08/2026
LiveWorld continues to Increase its AI investment CAMPBELL, Calif. and NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- LiveWorld, Inc. (OTC Markets: LVWD), today announced financial results for second quarter 2026. Three [...]
Ventripoint Expands Subscription Access for FDA-Cleared AI Cardiac Imaging
12/08/2026
Commercial initiative aims to make VMS+ easier for hospitals to evaluate and adopt TORONTO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV: VPT; OTC: VPTDF), a [...]
Kyowa Kirin Introduces Family Outreach Initiative to Support Families Living with XLH
12/08/2026
New resources and events help guide meaningful conversations about the hereditary nature of XLH PRINCETON, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd., [...]
Conavi Medical Corp. Announces Closing of $10M Public Offering
12/08/2026
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“ Conavi ” or the “ Company ”), a commercial stage [...]
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
12/08/2026
WILMETTE, Ill., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with [...]
Targeting The Mutant: NTHI’s NEO100 Data Could Open a New Front in the Fight Against Brain Cancer
12/08/2026
DALLAS, Aug. 12, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has delivered the kind of clinical update that can change the conversation around a small biotechnology company: its Phase 2a study of [...]
Inc. Recognizes U.S. Oral Surgery Management as One of the Fastest-Growing Private Companies in America
12/08/2026
USOSM Earns a Place on the Inc. 5000 List for Revenue Growth IRVING, Texas, Aug. 12, 2026 (GLOBE NEWSWIRE) -- For the second year in a row, U.S. Oral Surgery Management ( USOSM ) has been named to the Inc. 5000 list, an [...]
Rakovina Therapeutics Announces Closing of First Tranche, Upsize and Extension of Non-Brokered Private Placement
12/08/2026
Expanded financing broadens Rakovina’s strategic investor base and reinforces confidence in its AI-powered oncology platform VANCOUVER, British Columbia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX [...]
Expanded Access Case Report of SNIPR001, an Engineered CRISPR Medicine, in Rare Intracellular E. coli Disease Published in Clinical Infectious Diseases
12/08/2026
COPENHAGEN, Denmark, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SNIPR today announced the publication of a peer-reviewed expanded access case report in Clinical Infectious Diseases https://doi.org/10.1093/cid/ciag446 describing [...]
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
12/08/2026
BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases [...]
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
12/08/2026
Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 [...]
BioPorto A/S to host an investor webcast on the results for the first half of 2026
12/08/2026
BioPorto A/S to host an investor webcast on the results for the first half of 2026 COPENHAGEN, DENMARK, August 12, 2026 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), announced today that CEO [...]
Anteris Technologies Announces Results for the Second Quarter of 2026
12/08/2026
MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, [...]
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
12/08/2026
GRAND CAYMAN, Cayman Islands, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference ( [...]
FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares
12/08/2026
FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares AUSTIN, Texas and LYON, France, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (NASDAQ: FOCL) (the “Company”), a global leader in robotic [...]
NovelMed Advances NM5072 for Multiple Ocular Disorders
11/08/2026
Key Highlights Multi-indication precedent: Biogen’s approximately $5.6 billion acquisition of Apellis added EMPAVELI for PNH and SYFOVRE for GA, both of which contain pegcetacoplan. Primate proof of concept: A single [...]
Five Years of Unprecedented Growth: TimelyCare Redefines Student Well-Being
11/08/2026
Latest Inc. 5000 ranking cements TimelyCare’s position as a trusted, high-impact partner for educational communities. Fort Worth, TX, Aug. 11, 2026 (GLOBE NEWSWIRE) -- TimelyCare, education’s most trusted virtual care [...]
Rampart Withdraws Appeal of USPTO’s Invalidation Decision
11/08/2026
ST. PAUL, Minn., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Egg Medical announced today that Rampart IC, LLC (“Rampart”) withdrew its appeal of the USPTO’s reexamination decision that the claims of Rampart’s U.S. Patent No. 11, [...]

Pages